Low- versus high-dose rituximab for rheumatoid arthritis: A systematic review and meta-analysis

Arthritis Care and Research

Volumn 66, Issue 2, 2014, Pages 228-235

  Bredemeier, Markus ^a   De Oliveira, Fernando K ^a   Rocha, Cláudia M ^a  

^a HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ACR20 SCORE; ACR50 SCORE; ACR70 SCORE; ADVERSE OUTCOME; COHORT ANALYSIS; DAS28; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCORE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOW DRUG DOSE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84893424491     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22116     Document Type: Review

References (44)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-20.
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
4. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39-46.
5. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
6. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69: 1629-35.
7. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Efficacy of different doses of rituximab for the treatment of RA: data from the CERERRA Collaboration [abstract]. Ann Rheum Dis 2012; 71 Suppl: 62.
8. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49: 1683-93.
9. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011; 63: 603-8.
10. Van Vollenhoven RF,. More or less rituximab? Biology and clinic, regulators and researchers. Arthritis Rheum 2011; 63: 594-6.
11. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011. URL: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/front-page.htm.
12. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. Lee YH, Bae SC, Song GG,. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011; 31: 1493-9.
15. Hernandez-Cruz B, Garcia-Arias M, Ariza Ariza R, Martin Mola E,. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety. Reumatol Clin 2011; 7: 314-22. In Spanish.
16. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
17. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: non-inferiority clinical trials (draft). FDA/CDER/CBER; March 2010. URL: http://www.fda.gov/downloads/Drugs/./Guidances/UCM202140.pdf.
18. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ,. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 2006; 59: 342-53.
19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
20. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr,. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-87.
21. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D,. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-55.
22. Agency for Healthcare Research and Quality. Assessing equivalence and non-inferiority (draft). Rockville (MD): Agency for Healthcare Research and Quality; 2011. URL: http://www.effectivehealthcare.ahrq.gov/ehc/products/365/ 802/Equivalence-Non-inferiority-DraftReport-20111004.pdf.
23. Treadwell J, Uhl S, Tipton K, Singh S, Santaguida L, Sun X, et al. Assessing equivalence and noninferiority: methods research report. AHRQ publication no. 12-EHC045-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2012. URL: http://www.effectivehealthcare.ahrq.gov/ehc/products/365/ 1154/Assessing-Equivalence-and-Noninferiority-FinalReport-20120613.pdf.
24. Lange S, Freitag G,. Choice of delta: requirements and reality. Results of a systematic review. Biom J 2005; 47: 12-27.
25. Chatzidionysiou K, Lie E, Nasonov EL, Lukina G, Hetland ML, Tarp U, et al. Efficacy of different doses of rituximab for the treatment of rheumatoid arthritis: data from the CERERRA Collaboration [abstract]. Arthritis Rheum 2011; 63 Suppl: S643.
26. Peterfy C, Emery P, Tak P, Ostergaard M, DiCarlo J, Otsa K, et al. Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: results from a randomised, placebo-controlled trial in patients (pts) with rheumatoid arthritis (RA-SCORE) [abstract]. Ann Rheum Dis 2011; 70 Suppl: 152.
27. Roche Pharmaceuticals. A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate (protocol number: MA21056). Clinical trial result information. Basel: Hoffmann-La Roche; 2011. URL: http://www.roche-trials.com/studyResultGet.action?studyResultNumber= MA21056.
28. Dougados M, Rouanet S, Sibilia J, Combe BG, Le Loet XX, Tebib JG, et al. One single infusion of rituximab 1g might be sufficient in the long-term management of rheumatoid arthritis patients responding to a first cycle of rituximab (2 x 1g): results of a 2-year multi-center randomized controlled trial [abstract]. Arthritis Rheum 2011; 63 Suppl: S173.
29. Tak PP, Rigby W, Rubbert A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford) 2010; 49: i4.
30. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken) 2011; 63: 711-20.
31. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2012; 71: 351-7.
32. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol 2008; 35: 20-30.
33. Mease P, Szechinski J, Greenwald M, Leirisalo-Repo M, Kivitz A, Barile-Fabris L, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (D A N C E R) [abstract]. Arthritis Rheum 2005; 52 Suppl: S138-9.
34. Deodhar A, Isaacs J, Rigby W, Racewicz AJ, Abud-Mendoza C, McLean L, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum 2008; 58 Suppl: S302.
35. McGonagle D, Tan AL, Madden J, Taylor L, Emery P,. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 865-7.
36. Welsing PM, Borm GF, van Riel P,. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol 2006; 33: 501-7.
37. Vastesaeger N, Xu S, Aletaha D, St.Clair EW, Smolen JS,. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1114-21.
38. Graudal N, Jurgens G,. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010; 62: 2852-63.
39. Bertele' V, Assisi A, Di Muzio V, Renzo D, Garattini S,. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol 2007; 63: 879-89.
40. Erhorn S,. Rituximab (MabThera) in rheumatoid arthritis: non-NICE approved indications. Newcastle: NHS Regional Drug & Therapeutics Centre; July 2011. URL: http://www.nyrdtc.nhs.uk/docs/eva/Retuximab-non-NICE.pdf.
41. Gupta SK,. Intention-to-treat concept: a review. Perspect Clin Res 2011; 2: 109-12.
42. Conway R, Carey JJ,. Comment on: efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis. Results of a phase III randomized study (MIRROR) [letter]. Rheumatology (Oxford) 2011; 50: 631-2.
43. Tesfa D, Ajeganova S, Hagglund H, Sander B, Fadeel B, Hafstrom I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63: 2209-14.
44. Isvy A, Meunier M, Gobeaux-Chenevier C, Maury E, Wipff J, Job-Deslandre C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine 2012; 79: 365-9.